Enhancement of oral bioavailability of paclitaxel after oral administration of schisandrol B in rats

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 4, 2010, Pages 264-268

  Jin, Jing ^a   Bi, Huichang ^a   Hu, Jinqing ^a   Zhong, Guoping ^a   Zhao, Lizi ^a   Huang, Zhiying ^a   Huang, Min ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bioavailability; Paclitaxel; Pharmacokinetics; Rats; Schisandrol B

Indexed keywords

DOCETAXEL; GOMISIN A; PACLITAXEL; ANTINEOPLASTIC AGENT; CYCLOOCTANE DERIVATIVE; LIGNAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DOSE RESPONSE; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SCHISANDRACEAE; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYCLOOCTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INJECTIONS, INTRAVENOUS; LIGNANS; MALE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; SCHISANDRA;

EID: 77955294499     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.705     Document Type: Article

References (19)

1. Huizing MT, Misser VH, Pieters RC et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404.
2. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004-1014.
3. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235: 179-192.
4. Bardelmeijer HA, Ouwehand M, Beijnen JH, et al. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 2004; 22: 219-229.
5. Sparreboom A, van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
6. Varma MV, Ashokraj Y, Dey CS et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359.
7. Zhang S, Sagawa K, Arnold RD et al. Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: In vitro and in vivo. J Pharm Sci 2009; 99: 430-441.
8. Choi BC, Choi JS, Han HK. Altered pharmaco-kinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm 2006; 323: 81-85.
9. Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 2004; 57: 313-318.
10. Li X, Choi JS. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm 2007; 337: 188-193.
11. Choi JS, Shin SC. Enhanced paclitaxel bioavail-ability after oral coadministration of paclitaxel prodrug with naringin to rats. Int J Pharm 2005; 292: 149-156.
12. Min HY, Park EJ, Hong JY et al. Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg Med Chem Lett 2008; 18: 523-526.
13. Lai L, Hao H, Wang Q et al. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos 2009; 37: 2399-2407.
14. Yoo HH, Lee M, Lee MW et al. Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2. Planta Med 2007; 73: 444-450.
15. Fong WF, Wan CK, Zhu GY et al. Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med 2007; 73: 212-220.
16. Huang M, Jin J, Sun H et al. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 2008; 62: 1015-1026.
17. Qin XL, Bi HC, Wang XD et al. Mechanistic understanding of the different effects of Wuzhi tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of tacrolimus (FK506). Int J Pharm 389: 114-121.
18. Choi JS, Li X. The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur J Pharm Sci 2005; 24: 95-100.
19. Kimura Y, Aoki J, Kohno M et al. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 2002; 49: 322-328.